GT Metabolic Solutions, Inc.
13
6
9
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Creation of Compression Anastomosis Using the GT Metabolic Magnet System
Role: lead
MagDI Italian Study
Role: lead
MagDI U.S. Registry
Role: lead
Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
Role: lead
GT Metabolic Magnet System in Adults With Gastrointestinal Disorders
Role: lead
Magnetic Duodeno-Ileal Chile Study
Role: lead
MagDI Canada Study
Role: lead
MagDI Australia Study
Role: lead
Magnetic Jejuno-Ileal Diversion Study ("MJI Study")
Role: lead
Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosis System in Mexico
Role: lead
Magnetic Gastro-Ileal or Gastro-Jejunal Diversion Study ("MGI/MGJ Study")
Role: lead
MagDI Diversion Feasibility Study
Role: lead
Creation of Side-to-Side Compression Anastomosis Using the Magnetic Anastomosis System
Role: lead
All 13 trials loaded